



breast cancer
care wa



Annual financial report

For the year ending 31 December 2023

Contents

Information register	3
Directors' report	4
Results from operations	8
Directors	10
Statement of profit or loss and other comprehensive income	14
Statement of financial position	15
Statement of changes in equity	16
Statement of cash flows	17
Notes to the financial statements	18
Directors' declaration	30
Auditor's independence declaration	31
Independent auditor's report	32

Information register

ABN

77 221 238 430

Board of directors

Role	Name
Chairman	Malcolm Day
Deputy-Chairman	Simon Martin
Director	Pauline Gately
Director	Adam Marshall
Director	Brendan Cooley
Director	Dr Danielle Meyrick
Director	Zoe McAlpine (resigned May 2023)
Director	Ellie Scarf (resigned Sep 2023)

Registered office

80 Railway Street
Cottesloe WA 6011

Bankers

National Australia Bank
464 Hay Street
SUBIACO WA 6008

ANZ Bank
1275 Hay Street
WEST PERTH WA 6005

Bendigo Bank
9 Adelaide St
Fremantle WA 6160

Macquarie Bank
Level 4, 40 Kings Park Road
West Perth WA 6005

Auditors

AMW Audit
Unit 8
210 Winton Rd
Joondalup WA 6027

Directors' report

Our directors present this report of Breast Cancer Care WA Inc.

Board

The names of each person who has been a director during the period and at the date of the report are:

Name	Date Appointed	Date Ceased
Malcolm Day	2004	Current
Simon Martin	February 2009	Current
Pauline Gately	March 2014	Current
Adam Marshall	December 2016	Current
Brendan Cooley	October 2020	Current
Zoe McAlpine	October 2021	May 2023
Ellie Scarf	October 2020	Sep 2023
Dr Danielle Meyrick	February 2023	Current

Principal activities

Breast Cancer Care WA provides a supportive care service for those affected by breast cancer in Western Australia. It recognises that individuals have different needs and therefore require different levels of response. The supportive care provision is evidence-based and customised to meet the individual or family's needs, which may require liaison, collaboration, or referral to another agency.

The principal activities of Breast Cancer Care WA during the period consisted of providing personalised emotional, mental health, practical, and financial support to people affected by breast cancer and educating the community to increase awareness and early detection of breast cancer.

Collaboration is a core value for Breast Cancer Care WA. We work with colleagues in the health system and other service providers to enhance the patient experience.

In 2023, 62% of our clients were referred by health professionals, including Breast Surgeons, Oncologists, Breast Care Nurses, Oncology Nurses, Social Workers and Lymphoedema therapists. We connect clients with Cancer Council Western Australia, Breast Cancer Network Australia and other community support agencies to broaden their support network.

- **Specialist Breast Care Nursing:** Breast care nurses are patient advocates. They are our clients' main contact and source of information throughout their treatment, empowering them in their relationships with their healthcare team. Breast care nurses also provide emotional support for the client and their family, as well as evidence-based information and resources to help them live well with, or after, cancer.

- **Counselling:** Our team of specialist counsellors provide mental health support to our clients and their families, helping them to cope with changes, challenges, and uncertainty during their treatment and beyond. One-on-one counselling is available in person, over the phone, at home visits or online.
- **Financial hardship support:** A breast cancer diagnosis can have a huge financial burden on a family. Many of our clients are forced to stop working, making it difficult to meet the cost of running a household. Financial support is available to help our clients with utility bills, fuel or groceries. We also refer clients to appropriate community support services for additional support.
- **Practical support:** Breast cancer treatment can reduce our clients' capacity to carry out everyday tasks we take for granted. Some help around the house can make a world of difference to their wellbeing. We provide short-term, practical support by arranging services like household cleaning, garden maintenance or transport to and from appointments.
- **Monthly support groups:** Our support groups are facilitated by specialist counsellors. These groups provide a space for our clients to share helpful information and coping strategies with their peers. These include groups for young people, people with early breast cancer, people with metastatic breast cancer and partners of people with breast cancer.
- **Therapeutic workshops:** Therapeutic workshops allow our clients to explore their feelings and the burden of breast cancer through art therapy, meditation, and mindfulness. The workshops focus on practical strategies and problem-solving skills that help people cope with breast cancer.
- **Breast awareness:** We conduct community education on the importance of early intervention and screening for breast cancer.

- **Survivorship:** Australia has one of the best breast cancer survival rates in the world. We offer our clients evidence-based information and support programs for breast cancer survivors transitioning from active treatment to post-treatment life. Additionally, we support individuals with metastatic breast cancer in living well with a chronic condition.

Comprehensive support services overview

Our team and impact

Our team, consisting of six specialist breast care nurses, five counsellors, a support services coordinator, and a support services manager, plays a crucial role in providing emotional support and information throughout various phases of care, including diagnosis, treatment, survivorship, and end-of-life care.

In 2023, we empowered 1,737 individuals with breast cancer and their families (including 329 in regional and remote areas) through our services. This is an increase from 1,478 in 2022. We admitted 969 new clients to our service in 2023, up from 801 in 2022.

Client demographics and engagement

Primary breast cancer	73.05%
Reoccurrence	2.30%
Metastatic breast cancer	21.18%
Partners/close family members	3.3%
Genetic pre-disposition	<1%

Each client's complexity often requires a broad range of support services, with the average engagement period being two years. Clients with metastatic disease can remain engaged longer as they manage a chronic condition.

In 2023, 12.5% of our new clients had a metastatic breast cancer diagnosis, leading us to increase the metastatic breast care nurse position and expand our practical and financial assistance for this group.

Support groups

Our support groups, facilitated by specialist counsellors, provide vital peer and mental health support. In 2023, we held 142 support group meetings across various locations, including:

- Primary breast cancer (6 groups)
- Young women with primary breast cancer (3 groups)
- Metastatic breast cancer (5 groups)
- Young women with metastatic breast cancer (1 group)
- Partners' support group (1 group).

These groups help participants feel less distressed, less alone, and more optimistic about the future.

Survivorship

Living Well Program was initiated in 2023. We offered 38 activities to help clients across WA live as well as possible with and after breast cancer. Our pilot program engaged 264 clients. This program includes workshops, webinars, and activities such as:

- Survivorship care plan
- Calming the stress response
- Embracing uncertainty
- Bringing values to life
- Creative self-care
- Clay therapy
- Advanced care planning
- Mindfulness practice
- Chair therapy yoga.

These programs promote well-being, self-care, and skill development to address the physical, psychological, and social impacts of breast cancer. Activities are delivered both in-person and online to maximise accessibility.

Service hours and client support

We dedicated 7,340 hours to serving WA, assisting clients through various programs:

Breast care nursing:	838 clients
Counselling:	715 clients
Financial hardship support:	480 clients
Practical support:	236 clients
Support groups:	276 clients
Living well:	246 clients



Results from operations

Operations review

Comprehensive profit of \$462,293 was made during January to December 2023 compared to the budgeted deficit of \$24,938.

The application of costs for the year ended 31 December 2023 was as follows:

Employment Costs:	51%
Operational Cost:	11%
Administration Costs	6%
Fundraising Costs:	5%
Growth Initiatives	27%
Total Applied Funds	100%

Further details of Breast Cancer Care WA Inc. results can be found in notes 4 and 5 to the financial statements.

The continued high client numbers placed significant demands on our Support Services Team, and a sixth Breast Care Nurse and additional Counselling hours were added to ensure continued support for each of our clients. The growth in demand for our services has continued and confirms the foresight of our Board of Directors when commencing our growth strategy in 2016. Since the commencement of this strategy, income has more than doubled to meet the growing demand for our services.

Again in 2023, we faced the cancellation of major events, including our flagship fundraising event the Long Table Lunch. The team continue to innovate and find new approaches to what have become everyday challenges, and fundraising initiatives including an online auction (Bids for Breastfriends), our golf day continued and grew in participants, and our online presence and growth of online service delivery continued to grow. Other achievements include business process improvements, mobilising our

team and developing new efficiencies to drive increased service delivery.

As an organisation dedicated to providing personalised support services tailored to the needs of each individual client, our greatest investment and our greatest asset is our Team and support from our donors and volunteers, without whom our Support Services would not be possible.

Expenses were significantly reduced wherever possible to minimise the impact of the challenging fundraising period, and to position the organisation for a strong start to 2024, as evidenced by the \$63,088 net deficit result against a budgeted deficit of \$274,872.

Our growth initiatives strategy to encourage donors to make regular monthly contributions continues, so that we can be assured of sustainable income to fund our vital services. This strategy requires significant upfront costs, which we recognised would be high at the outset, and we carefully weighed our decision against the expected benefit of the future income streams and the resources available to us. Eight years into the program, targets are being met and key indicators continue to perform as originally planned. The implementation of our growth initiatives strategy was and remains a sound decision, as demonstrated by our ability to meet the ongoing client demand for services.

The reported deficit in operations of \$63,088 (\$211,784 better than budgeted) is the result of strong financial management throughout the year and savings in expenses across the board.

With over 1,800 people in WA diagnosed with breast cancer each year, it is vital that we not only invest in delivering support services today, but also in creating sustainable

income sources to allow us to be here for those affected in the future.

Cash and invested funds on 31 December 2023 total **\$3,174,428**
(31 December 2022 **\$2,617,719**).

Strategic horizon

In 2023 we welcomed new CEO Max Clarke to lead Breast Cancer Care WA into the future and we are pleased with the progress being made.

We continue to endeavour to meet and surpass our goals in providing support services for all Western Australians whose lives have been affected by breast cancer. The Directors and CEO are confident that ongoing sound financial management will maintain support services delivery at current levels, and that the organisation will move strongly forward.

We extend our heartfelt thanks to our supporters who make our work possible, and to the Leadership and Team who work tirelessly to ensure that every person affected by breast cancer in WA has access to our support.

Signed in accordance with a resolution of the directors.

For and on behalf of the Board:



Malcolm Day

Director and Chairman
27 May 2024



Simon Martin

Director and Vice-Chairman
28 May 2024

Directors' qualifications



Malcolm Day Chair

Bachelor of Applied Science Surveying and Mapping, Licensed Surveyor

Previously employed as a Senior Civil Engineer. Non-executive Director of European Lithium Ltd (listed on the Australian and German Stock Exchanges), previously a member of the Australian Institute of Company Directors.

Managing Director of Delecta Ltd (listed on the Australian Stock Exchange).

Founder of the annual Boobalicious Ball.

Special Responsibilities: Chairman, Investment Committee



Simon Martin Vice Chair

BComm, CA GAICD

An executive with over 20 years' experience across all facets of business management. Simon's previous roles include General Manager for Network Ten Perth and CEO for Cystic Fibrosis Australia.

Simon is currently the Chief Operating Officer for WA Primary Health Alliance.

Special Responsibilities: Vice Chairman, Investment Committee



Pauline Gately

BA Hons (Econ), Grad Dip Acc, GAICD

A highly accomplished economist, investment strategist and Non-Executive Director, Pauline, has experience across a range of Board positions in mining and resources, financial technology, and FMCG.

Pauline has a track record of successfully navigating changing directional points. Her Board contributions are underpinned by senior roles in international investment banking, including investment strategy and funds management.

A graduate of the Australian Institute of Company Directors, Pauline is currently Non-Executive Chair of Australian Primary Hemp Ltd (ASX: APH) and Non-Executive Director of Ardiden Ltd (ASX: ADV).

Special Responsibilities: Investment Committee



Adam Marshall

**2:1 BA Economics,
Goldsmiths College,
University of London**

Adam is the Chief Executive Officer of Marketforce, a member of the Clemenger BBDO Network. He has over twenty years media experience and has worked in the UK and Asian markets. He is a regular commentator on media matters in the broader media and has lectured on advertising and marketing at each of Perth's universities and at AdSchool.

Adam has previously been Chairperson of the Oasis Committee the WA advertising industry's charity association and is a board member of charity FTT, a group dedicated to raising funds for disabled athletes.

**Special Responsibilities:
Marketing and
Communications**



Brendan Cooley

**MBA (Leadership), GAICD,
Graduate Certificate in
Business, Diploma Transport &
Distribution**

Brendan is a 40 under 40 winner and an accomplished Director with broad and strategic experience. He is Managing Director at a privately held maritime company based in Fremantle and joined the Breast Cancer Care WA board in October 2020 after a long association with the organisation.

Post-graduate qualifications in leadership, sustainability, business administration, and transport and logistics, underpin Brendan's substantial experience in the water transport industry in diverse roles including commercial, operations, corporate development, and sustainability.

With over 10 years' global executive experience across private sector and community organizations, he operates with a strong emphasis on advocacy, governance, and strategy, within dynamic and inspiring organisations.



Dr Danielle Meyrick **BSc.(Hons), PhD, MD**

Dr Danielle Meyrick has over two decades' experience in development and clinical delivery of novel anti-cancer therapies, and is currently Chief Scientific Officer, Research and Insights at GenesisCare.

Danielle holds a Doctor of Medicine and a PhD in Radiopharmaceutical Chemistry and previously held the role of Chief Medical Officer, Asia Pacific, for Telix Pharmaceuticals, where she led the clinical science program globally and was responsible for medical affairs in the Asia Pacific region.

Danielle has held senior roles across the public, university and private sectors, and has a strong clinical development track record in a number of regulatory settings, including the US and China, as well as commercial radiopharmaceutical product launch experience in Asia Pacific markets.

Danielle has served on councils and committees for the Australian Institute of Nuclear Science and Engineering and ANSTO, has published peer-reviewed articles and technical reports across a breadth of topics in chemistry and medicine and is committed to supporting access for all patients to leading edge, compassionate, holistic medical and health care.



Zoe McAlpine

B.Comm

With 20 years of leadership experience, seven of those at the helm of Breast Cancer Care WA, Zoe was delighted to be invited to join the Board of Directors in 2021.

Zoe has experience across the for purpose, education and retail sectors, with a passion for developing positive workplace culture, and growing and diversifying income. At the heart of Zoe's approach is always 'the people' - the team she leads, the people she serves, and the supporters who make it possible.

Her commitment at Breast Cancer Care WA was always to ensure that the organisation continued to exist not only today, but for the growing number of people diagnosed with breast cancer in the future, including those facing metastatic disease with continuing support needs.

Zoe was also a voluntary director on the board of the Cancer Wellness Centre: an organisation committed to fostering collaboration amongst cancer support charities in WA.



Ellie Scarf

BA, LLB

Ellie is the CEO and Founder of Lucent Global, a coaching and leadership development organisation with a focus on senior level transitions into organisations. She is a coach, facilitator and business owner with a passion for evidence-based approaches to optimising individual, team and organisational performance.

Ellie has worked in people focussed roles for the past 18 years, including coaching and facilitating, leading sales capability and strategy within a billion dollar organisation, learning and development roles and being part of a human centred innovation team. Ellie is also a qualified lawyer who started her career within top tier law firms in WA and NSW.

Special Responsibilities:
People and culture



Statement of profit or loss and other comprehensive income

14

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	31 Dec 2023	31 Dec 2022
INCOME		\$	\$
Fundraising Income	4a	5,095,732	4,207,914
Investment Income	4b	123,099	(84,857)
Other Income	4c	-	4,637
Total revenue & other income		5,218,831	4,127,694
EXPENDITURE			
<i>Operational</i>	5	(513,110)	(439,363)
<i>Fundraising</i>	6	(254,780)	(222,840)
<i>Administration</i>	7	(303,315)	(286,877)
<i>Employment</i>	8	(2,412,173)	(2,144,507)
<i>Growth initiatives</i>	9	(1,273,160)	(1,097,195)
Total		4,756,538	(4,190,782)
NET SURPLUS/(LOSS) FOR THE YEAR		462,293	(63,088)
TOTAL COMPREHENSIVE INCOME/ (EXPENSE) FOR THE YEAR		462,293	(63,088)

The statement of profit or loss and other comprehensive income is to be read in conjunction with the attached notes.

Statement of financial position

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	31 Dec 2023	31 Dec 2022
ASSETS		\$	\$
Current assets			
Cash and cash equivalents	10	1,513,656	1,414,445
Trade and other receivables	11	126,841	187,612
Prepayments		11,423	35,119
Total current assets		1,651,920	1,637,176
Non-current assets			
Plant and equipment	12a	53,352	75,559
Financial assets	13	1,660,772	1,203,274
Right of use assets	12b	18,810	52,498
Total non-current assets		1,732,934	1,331,331
TOTAL ASSETS		3,384,854	2,968,507
LIABILITIES			
Current liabilities			
Trade and other payables	14	115,007	137,354
Provisions	15	155,591	150,189
Lease liabilities	16	18,810	34,560
Total current liabilities		289,408	322,103
Non-current liabilities			
Provisions	15	42,228	37,541
Lease liabilities	16	-	17,938
Total non-current liabilities		42,228	55,479
TOTAL LIABILITIES		331,636	377,582
NET ASSETS		3,053,218	2,590,925
FUNDS			
Accumulated funds		3,053,218	2,590,925
TOTAL FUNDS		3,053,218	2,590,925

The statement of financial position is to be read in conjunction with the attached notes.

Statement of changes in equity

16

FOR THE YEAR ENDED 31 DECEMBER 2023

	Accumulated funds	Total funds
	\$	\$
Balance at 1 January 2022	2,654,013	2,654,013
Net surplus for the year	(63,088)	(63,088)
Balance at 31 December 2022	2,590,925	2,590,925
Balance at 1 January 2023	2,590,925	2,590,925
Net surplus for the year	462,293	462,293
Balance at 31 December 2023	3,053,218	3,053,218

The statement of change of funds is to be read in conjunction with the attached notes.

Statement of cash flows

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	31 Dec 2023	31 Dec 2022
CASH FLOWS FROM OPERATING ACTIVITIES		\$	\$
Receipts from:			
Fundraising income		5,152,263	4,181,767
Investment income		72,754	49,866
Other income		-	4,637
<i>Payments to suppliers & employees</i>		(4,882,557)	(4,270,270)
<i>Cash flows from other operating activities</i>		221,861	84,559
Net cash from operating activities	17	564,321	50,559
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property plant and equipment		(11,927)	(27,195)
Purchase of financial assets		(2,549,744)	(647,494)
Sale of financial assets		2,133,403	668,081
Net cash used in investing activities		(428,268)	(6,608)
CASH FLOWS FROM FINANCING ACTIVITIES			
Other cash items from financing activities			-
Lease payments (principal and interest)		(36,842)	(34,528)
Net cash used in financing activities		(36,842)	(34,528)
Net increase in cash and cash equivalents		99,211	9,423
Cash and cash equivalents at the beginning of the year		1,414,445	1,405,022
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	10	1,513,656	1,414,445

The statement of cash flows is to be read in conjunction with the attached notes.

Notes to the financial statements

FOR THE YEAR ENDED 31 DECEMBER 2023

1. CORPORATE INFORMATION

The financial statements of the not-for-profit entity, Breast Cancer Care WA Inc for the year ended 31 December 2023 were authorised for issue in accordance with a resolution of the directors on 27 June 2024.

Breast Cancer Care WA Inc. is an incorporated association operating exclusively in Australia. The nature of the entity's operations and principal activities are described in the director's report.

2. CHANGES IN ACCOUNTING POLICIES

The accounting policies and methods of computation adopted in the preparation of the previous year's financial report are consistent with those adopted and disclosed in the entity's annual financial report for the financial year ended 31 December 2023. The entity is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of preparation

These general-purpose financial statements have been prepared in accordance with the requirements of the Associations Incorporations Act [WA], Australian Accounting Standards – Simplified Disclosures, other authoritative pronouncements of the Australian Standards Board, Urgent Issues Group Interpretations and the ACNC Act 2012. The entity is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

Historical cost accounting

The financial statements have been prepared based on historical cost except for Equity Instruments which are measured at fair value.

Functional currency

The financial report is presented in Breast Cancer Care WA Inc.'s functional currency which is the Australian dollar.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise.

(b) Significant accounting judgements, estimates and assumptions

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and other various factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

Significant accounting estimates and assumptions

The key estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of certain assets and liabilities within the next annual reporting period are:

- **Provisions for employee benefits**
Provisions for employee benefits payable after 12 months from the reporting date are based on future wage and salary levels, experience of employee departures and periods of service, as discussed in Note 3(l).

The amount of these provisions would change should any of these factors change in the next 12 months.

(c) Revenue recognition

Revenue is recognised under AASB 1058 or AASB 15 when appropriate. In cases where there is an enforceable contract with a customer with 'sufficiently specific' performance obligations, the transaction is accounted for under AASB 15 where income is recognised when (or as) the performance obligations are satisfied (i.e.) when it transfers control of a product or service to a customer). Revenue is measured based on the consideration to which Breast Cancer Care WA expects to be entitled in a contract with parties. In other cases, AASB 1058 applies when a NFP entity enters into transactions where the consideration to acquire an asset is significantly less than the fair value of the asset principally to enable the entity to further its objectives and the excess of the asset recognised (at fair value) over any 'related amounts' is recognised as income immediately.

(i) Donations & growth initiatives

Donations collected, including cash and goods for resale, are recognised as revenue when Breast Cancer Care WA gains control of the asset.

(ii) Investment income

Investment income comprises interest, dividends, trust distributions and realised gains on investments. Interest income is recognised as it accrues, using the effective interest method. Dividends and distributions from entities are recognised when the shareholder's right to receive payment has been established, provided

it is probable that the economic benefits will flow to the entity and the amount of income can be measured reliably.

(iii) Sale of goods

Revenue from the sale of goods is measured at fair value received or receivable and is recognised when control of the goods passes to the customer.

(iv) Sponsorships & grants

Sponsorships and grants are recognised when there is reasonable assurance that the grant will be received, and all attaching conditions have been complied with.

Under AASB 1004, most grant income was recognised as revenue on receipt. Under AASB 1058 and AASB 15, where an agreement is enforceable and contains sufficiently specific performance obligations, the revenue is either recognised over time as the work is performed or recognised at the point in time that the control of the services pass to the customer.

Having reviewed the grants received, The Directors have determined that no grants provided to the entity during the period create a sufficiently specific and enforceable contract to require a change in treatment from prior periods.

(v) Volunteer services

The Directors have decided not to recognise volunteer services within the financial statements, given the true value of these services is not reliably measurable in financial terms.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to a particular category, they have been allocated to activities on a basis consistent with use of the resources.

Fundraising costs are those incurred in seeking voluntary contributions by donation and do not include costs of disseminating information relating to the activities carried on by the entity. Costs incurred in obtaining regular donations are expensed in full when the donor is registered to make a future donation. These costs have been disclosed as growth initiatives in the Financial Statements.

Operational costs are those costs directly incurred in supporting the objects of the entity.

Administration costs are those costs incurred in connection with administration of the entity and compliance with constitutional and statutory requirements.

Employment costs have been incurred in order to service the operational activities of the entity, predominantly the professional team to deliver support services to people affected by breast cancer, administer those services and assist with fundraising activities and the coordination of volunteers. An allocation of employment costs to each category is provided at note 8.

(e) Cash and cash equivalents

Cash and short-term deposits in the statement of financial position is comprised of cash at bank and in hand, and short-term deposits with an original maturity of six months or less.

For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts.

(f) Trade and other receivables

Trade receivables, which generally have 30-90-day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts.

Breast Cancer Care WA applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Bad debts are written off when identified.

Other receivables include donations which are accrued when it is probable that funds will be received and can be reliably measured.

(g) Plant and equipment

Plant and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses.

Depreciation is calculated on a straight-line basis over the estimated useful life of the assets as follows:

Plant and equipment 3 to 5 years

Motor Vehicles 5 years

Furniture and Fixtures 3 to 5 years

The assets' residual values, useful lives and amortisation methods are reviewed, and adjusted if appropriate, at each financial period.

Impairment

The carrying values of plant and equipment are reviewed for impairment at each reporting date, with recoverable amount being estimated when events or changes in circumstances indicate that the carrying value may be impaired.

The recoverable amount of plant and equipment is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

For an asset that does not generate largely independent cash inflows, recoverable amount is determined for the cash-generating unit to which the asset belongs, unless the asset's value in use can be estimated to be close to its fair value.

Impairment exists when the carrying value of an asset or cash-generating units exceeds its estimated recoverable amount. The asset or cash-generating unit is then written down to its recoverable amount.

(h) Financial investments

Recognition, initial measurement and derecognition

Financial investments are recognised when Breast Cancer Care WA becomes a party to the contractual provisions of the financial

instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of Financial Investments is described below.

The fair value of investments that are actively traded in organised financial markets is determined by reference to quoted market bid prices at the close of business on the reporting date. For investments with no active market, fair value is determined using valuation techniques. Such techniques include using recent arm's length market transactions, reference to the current market value of another instrument that is substantially the same, discounted cash flow analysis and option pricing mode.

Financial investments are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred.

Classification of financial investments

Classifications are determined by both:

- The business model for managing the financial asset
- The contractual cash flow characteristics of the Financial Investments.

Classification and subsequent measurement of financial investments

Under AASB 9, the basis on which the Financial Investments are measured is relevant to the way they are classified. The identification can be initiated by an assessment of the following critical issues in relation to these assets:

- The objective of the entity's business model is to hold these assets only to collect cash flows, or to collect cash flows and to sell ("The Business Model Test") and
- The contractual cash flows of the assets give rise to contractual payments that are solely payments of principal and interest ("SPPI Test")

Both tests must be met in order to classify and measure the asset at:

- Amortised cost

- Equity instruments at fair value through Other Comprehensive Income (FVOCI)

Failing these tests requires the assets to be classed and measured at fair value through profit & loss (FVPL).

Financial investments at fair value through profit or loss (FVPL)

Financial investments that are held within a different business model other than 'hold to collect' or 'hold to collect and sell' are categorised at fair value through profit and loss. Further, irrespective of business model Financial Investments whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.

Given that the business model and contractual cash flows of the assets differ from the above tests, Breast Cancer Care WA has categorised the equity investments on hand at fair value through profit and loss.

(i) Impairment of financial investments at fair value through profit and loss

Breast Cancer Care WA follows the guidance of AASB 9 Financial Instruments to determine when a financial asset is impaired. The only impairment methodology under this standard uses more forward-looking information to measure the impairment under the 'Expected Credit Losses (ECL) model. Instruments within the scope of this model include Financial Investments measured at amortised cost and FVOCI.

(j) Trade and other payables

Trade payables and other payables are carried at amortised costs and represent liabilities for goods and services provided to Breast Cancer Care WA prior to the end of the period that are unpaid and arise when Breast Cancer Care WA becomes obliged to make future payments in respect of the purchase of these goods and services.

(k) Provisions

Provisions are recognised when Breast Cancer Care WA has a present obligation (legal or constructive) as a result of a past event,

it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

When Breast Cancer Care WA expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of comprehensive income net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a pre-tax rate that reflects the risks specific to the liability. When discounting is used, the increase in the provisions due to the passage of time is recognised as a borrowing cost.

(l) Employee entitlements

(i) Wages, salaries and annual leave

Liabilities for wages and salaries, including non-monetary benefits and annual leave expected to be settled within 12 months of the reporting date are recognised in other payables in respect of employees' services up to the reporting date. They are measured at the amounts expected to be paid when the liabilities are settled.

(ii) Long service leave

The liability for long service leave is recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method.

Consideration is given to the expected future salaries and wage levels, experience of employee departures and periods of service.

(m) Income tax

Breast Cancer Care WA Inc. is exempt from the payment of income tax under the provisions of Section 50-45 of the Income Tax Assessment Act 1997. The entity holds deductible gift recipient status.

(n) Other taxes

Revenues, expenses and assets are recognised net of the amount of GST except:

- when the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
- receivables and payables, which are stated with the amount of GST included.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.

Cash flows are included in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to, the taxation authority are classified as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority.

(o) Leases

At inception of a contract, the Association assesses whether a lease exists – i.e., does the contract convey the right to control the use of an identified asset for a period of time in exchange for consideration.

This involves an assessment of whether:

- The contract involves the use of an identified asset – this may be explicitly or implicitly identified within the agreement. If the supplier has a substantive substitution right, then there is no identified asset.
- The Association has the right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use.
- The Association has the right to direct the use of the asset i.e., decision-making rights in relation to changing how and for what purpose the asset is used.

At the lease commencement, the Association recognises a right-of-use asset and associated lease liability for the lease term. The lease term includes extension periods where the Association believes it is reasonably certain that the option will be exercised.

The right-of-use asset is measured using the cost model where cost on initial recognition comprises of the lease liability, initial direct costs, prepaid lease payments, estimated cost of removal and restoration less any lease incentives.

The right-of-use asset is depreciated over the lease term on a straight-line basis and assessed for impairment in accordance with the impairment of assets accounting policy. The right-of-use asset is assessed for impairment indicators at each reporting date.

The lease liability is initially measured at the present value of the remaining lease payments at the commencement of the lease. The discount rate is the rate implicit in the lease, however where this cannot be readily determined then the Association's incremental borrowing rate is used.

Subsequent to initial recognition, the lease liability is measured at amortised cost using the effective interest rate method. The lease liability is remeasured whether there is a lease modification, change in estimate of the lease term or index upon which the lease payments are based (e.g., CPI) or a change in the Association's assessment of lease term.

Where the lease liability is remeasured, the right-of-use asset is adjusted to reflect the remeasurement or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

The Association has elected to apply the exceptions to lease accounting for leases of low-value assets.

For these leases, the Association recognises the payments associated with these leases as an expense on a straight-line basis over the lease term.

	31 Dec 2023	31 Dec 2022
	\$	\$
4. INCOME		
(a) Fundraising income		
Donations & growth initiatives	4,543,398	3,394,814
Sponsorships and grants	552,334	813,100
	5,095,732	4,207,914

(b) Investment income		
Interest income	26,366	7,560
Other investment income	55,576	44,060
Net gain/(loss) on disposal of financial investments	3,149	(37,186)
Change in FV of available for sale	38,008	(99,291)
	123,099	(84,857)

	31 Dec 2023	31 Dec 2022
	\$	\$
(c) Other income		
Insurance recoveries	-	4,637
	-	4,637

	31 Dec 2023	31 Dec 2022
	\$	\$
5. OPERATIONAL		
Financial & practical support	(287,676)	(224,135)
Insurance	(53,768)	(29,549)
Advertising & promotions	-	(83,308)
Marketing expenses	(22,255)	-
Other operational expenses	(136,090)	(102,371)
	(513,110)	(439,363)

	31 Dec 2023	31 Dec 2022
	\$	\$
6. FUNDRAISING		
Events expenses	(42,248)	(32,635)
Marketing expenses	(54,187)	-
Advertising & promotions	-	(39,348)
Fundraising programs expenses	(22,255)	(46,452)
Other fundraising expenses	(136,090)	(104,405)
	(254,780)	(222,840)

	31 Dec 2023	31 Dec 2022
7. ADMINISTRATION	\$	\$
Administration	(43,288)	(33,763)
Consultants/agencies	(43,084)	(38,331)
Equipment & software	(26,561)	(58,121)
Other administration expenses	(190,382)	(156,662)
	(303,315)	(286,877)

	31 Dec 2023	31 Dec 2022
8. EMPLOYMENT	\$	\$
Operational	(1,285,201)	(1,247,171)
Fundraising	(345,813)	(437,414)
Administrative	(514,994)	(169,310)
Growth initiatives	(266,165)	(290,611)
	(2,412,173)	(2,144,506)

	31 Dec 2023	31 Dec 2022
9. GROWTH INITIATIVES	\$	\$
Fundraising programs expenses	(1,256,722)	(1,043,239)
Other growth initiatives expenses	(16,438)	(53,956)
	(1,273,160)	(1,097,195)

	31 Dec 2023	31 Dec 2022
10. CASH AND CASH EQUIVALENTS	\$	\$
Cash at bank and in hand	1,362,646	908,681
Short-term deposits	151,010	505,764
	1,513,656	1,414,445

Cash at bank earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and six months, depending on the immediate cash requirements of Breast Cancer Care WA, and earn interest at the respective short-term deposit rates.

	31 Dec 2023	31 Dec 2022
11. TRADE AND OTHER RECEIVABLES	\$	\$
Pledges Receivable	60,642	84,993
Net goods & services tax receivable	27,846	72,984
Other receivables	38,353	29,635
	126,841	187,612

Trade receivables, which generally have 30-90 day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts. Breast Cancer care applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Bad debts are written off when identified.

12. PLANT AND EQUIPMENT AND RIGHT OF USE ASSETS

(a) Plant and equipment	Furniture & fixtures	Office equipment	Trademarks & licences	Total
COST OR FAIR VALUE	\$	\$	\$	\$
At 31 December 2022	124,769	156,446	510	281,725
Additions	-	11,927	-	11,927
Write-off	-	-	-	-
AT 31 DECEMBER 2023	124,769	168,373	510	293,652
ACCUMULATED DEPRECIATION				
At 31 December 2022	73,176	132,990	-	206,166
Depreciation charge for the period	8,706	25,428	-	34,134
Write-off	-	-	-	-
AT 31 DECEMBER 2023	81,882	158,418	-	240,300
NET CARRYING AMOUNT				
At 31 December 2022	51,593	23,456	510	75,559
AT 31 DECEMBER 2023	42,887	9,955	510	53,352

(b) Right of Use Assets	Buildings	Other	Total
	\$	\$	\$
At 31 December 2022	52,498	-	52,498
Right of use assets			
Depreciation charge	(35,063)	-	(35,063)
Additions to right of use assets	1,375	-	1,375
AT 31 DECEMBER 2023	18,810	-	18,810

13. FINANCIAL INVESTMENTS AT FAIR VALUE THROUGH PROFIT & LOSS (FVPL) - (NON CURRENT)

	31 Dec 2023	31 Dec 2022
	\$	\$
LISTED INVESTMENTS AT FAIR VALUE IN:		
Fixed interest investments	227,309	253,266
Equity investments	1,106,409	843,266
Alternative investments	327,054	106,742
	1,660,772	1,203,274
MOVEMENT IN FINANCIAL ASSETS AT FVPL		
Beginning balance	1,203,274	1,360,336
Purchases	1,402,494	487,056
Net disposal of financial assets	(983,004)	(544,827)

Changes in fair market value	38,008	(99,291)
BALANCE AT THE END OF THE YEAR	1,660,772	1,203,274

All shares have no fixed maturity date or coupon rate. Fixed-interest-securities include corporate bonds, convertible notes and hybrid securities which have coupon rates varying from 2 per cent to 6 per cent and may have no fixed maturity date. The market value of these securities fluctuates from time to time.

14. TRADE AND OTHER PAYABLES (CURRENT)

	31 Dec 2023	31 Dec 2022
	\$	\$
Visa cards	360	17,091
Trade creditors	16,534	52,753
Other creditors	29,400	22,318
Accruals	56,112	32,607
Other	12,601	12,585
	115,007	137,354

Trade and other payables are carried at amortised costs and represent liabilities for goods and services provided to Breast Cancer Care WA prior to the end of the period that are unpaid and arise when Breast Cancer Care WA becomes obliged to make future payments in respect of the purchase of these goods and services.

15. PROVISIONS

	31 Dec 2023	31 Dec 2022
	\$	\$
CURRENT		
Employee entitlements - annual leave	123,812	95,587
Employee entitlements - long service leave	31,779	54,602
	155,591	150,189
NON - CURRENT		
Employee entitlements - long service leave	42,228	37,514
	42,228	37,514

16. LEASE LIABILITIES

	< 1 year	1 - 5 years	> 5 years	Total undiscounted lease liabilities	Lease liabilities included in the Statement of Financial Position
	\$	\$	\$	\$	\$
Balance at 31 December 2022	34,560	17,938			52,498
Balance at 31 December 2023	18,810	-			18,810

The Association leases offices at 80 Railway Street Cottesloe expiring in June 2024. An extension to the lease is provisional on the head leaser and confirmation has been treated as contingent. Other leases are maintained on a short-term basis and are treated on that basis.

17. RECONCILIATION OF NET SURPLUS FOR THE PERIOD TO NET CASH FLOW FROM OPERATIONS

	Note	31 Dec 2023	31 Dec 2022
		\$	\$
NET SURPLUS/(LOSS) FOR THE PERIOD		462,293	(63,088)
Depreciation & amortisation	12	34,134	30,030
Changes in fair value of financial investments	13	(38,008)	99,291
Net loss/(gain) on disposal of F] financial investments	4(b)	(3,149)	37,186
Lease payments showing as financing		36,843	34,528
(INCREASE)/DECREASE IN ASSETS			
Receivables		60,770	(119,942)
Prepayments		23,697	(9,457)
INCREASE/(DECREASE) IN LIABILITIES			
Trade creditors and accruals		(22,348)	4,475
Provision for employee benefits		10,089	37,536
Net cash inflow from operating activities		564,321	50,559

18. RELATED PARTIES AND RELATED PARTY TRANSACTIONS

(a) Directors' compensation

The directors act in an honorary capacity and receive no compensation for their services.

(b) Transactions with director-related entities

During the year, payments of \$3,270 were made to Lucent Global Pty Ltd for consulting services. Ms. Scarf, who was a director of the Association, is also the director of Lucent Global Pty Ltd. These services were provided under normal commercial terms and conditions.

No amounts are payable to or receivable from directors or director-related entities at the reporting date.

(c) Key management personnel

The compensation paid to those having authority for planning, directing and controlling the entity's activities, directly or indirectly (other than directors), during the year:

	31 Dec 2023	31 Dec 2022
	\$	\$
Short-term employment benefits	190,600	299,760
Post-employment benefits	20,425	30,376
Other long-term benefits	-	-
	211,025	330,136

19. AUDITOR'S REMUNERATION

Amounts received or due and receivable by auditors of Breast Cancer Care WA Inc. for:

	31 Dec 2023	31 Dec 2022
	\$	\$
- an audit of the financial statements	11,000	10,135

20. CONTINGENT ASSET AND CONTINGENT LIABILITIES

The directors are not aware of any Contingent Assets and Contingent Liabilities that existed as of 31 December 2023.

21. COMMITMENTS

The directors are not aware of any commitments, other than those already disclosed, that existed at 31 December 2023.

22. COMPARATIVE FIGURES

Certain comparative figures have been restated to conform with current year's presentation.

Directors' declaration

The directors of Breast Cancer Care WA Inc declare that:

1. The financial statements, comprising the statement of profit or loss and other comprehensive income, statement of financial position, statement of cash flows, statement of changes in equity, and accompanying notes, are in accordance with the ACNC Act 2012 and:
 - a. comply with Australian Accounting Standards – Simplified Disclosures applicable to the Association; and
 - b. give a true and fair view of the Association's financial position as at 31 December 2023 and of its performance for the period ended on that date.
2. In the directors'/responsible entity's opinion, there are reasonable grounds to believe that the entity will be able to pay its debts as and when they become due and payable.

On behalf of the directors by:



Malcolm Day

Director and Chair
27 May 2024



Simon Martin

Director and Vice-Chair
28 May 2024



**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 60-40 OF THE
AUSTRALIAN CHARITIES AND NOT-FOR-PROFITS COMMISSION ACT 2012**

**TO THE DIRECTORS OF
BREAST CANCER CARE WA INC**

In accordance with Subdiv 60-C of the *Australian Charities and Not-for-profits Commission Act 2012*, I am pleased to provide the following declaration of independence to the directors of Breast Cancer Care WA Inc. As the lead audit partner for the audit of the financial statements of Breast Cancer Care WA Inc for the year ended 31 December 2023, I declare that, to the best of my knowledge and belief, during the year ended 31 December 2023 there have been no contraventions of:

- i) the auditor independence requirements of the *Australian Charities and Not for Profits Commission Act 2012* in relation to the audit; and
- ii) any applicable code of professional conduct in relation to the audit.

Dated this 21st day of June 2024

AMW (AUDIT) PTY LTD

AMW AUDIT
Chartered Accountants

BILLY-JOE THOMAS
Director and Registered Company Auditor



INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF BREAST CANCER CARE WA INC

Qualified Opinion

We have audited the accompanying financial report of Breast Cancer Care WA Inc (the "Association") which comprises the statement of financial position as at 31 December 2023, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year ended on that date, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the financial report of Breast Cancer Care WA Inc has been prepared in accordance with *Division 60 of the Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) giving a true and fair view of the registered Association's financial position as at 31 December 2023 and of its financial performance for the year then ended; and
- (ii) complying with Australian Accounting Standards – AASB 1060: *General Purpose Financial Statements – Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities* and *Division 60 of Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for Qualified Opinion

Fundraising income (which includes cash donations, fundraising programs, event income and sponsorship and grants) are a significant source of revenue for Breast Cancer Care WA Inc. The Directors have determined that it is impracticable to establish control over the collection of fundraising income prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising revenue from this source was limited, our audit procedures with respect to fundraising income had to be restricted to the amounts recorded in the financial records. We therefore are unable to express an opinion whether fundraising income recorded by the Association is complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Association in accordance with the ACNC Act, the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110: *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Information Other than the Financial Report and Auditor's Report Thereon

The directors are responsible for the other information. The other information comprises the information included in the Association's annual report for the year ended 31 December 2023, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Association are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – AASB 1060: *General Purpose Financial Statements – Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities* and the ACNC Act and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Association's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.


Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Association's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Association to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.


We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



AMW AUDIT

Chartered Accountants

Address: Unit 8, 210 Winton Road, Joondalup, Western Australia



BILLY-JOE THOMAS

Director & Registered Company Auditor

Dated at Perth, Western Australia this 21st day of June 2024



breast cancer
care wa

80 Railway Street
Cottesloe WA 6011

(08) 9324 3703

info@breastcancer.org.au

ABN 77 221 238 430 DGR 900 496 628

breastcancer.org.au